Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa

被引:145
作者
Rice, Louis B.
机构
[1] Louis Stokes Cleveland VA Med Ctr, Med Serv, Cleveland, OH 44106 USA
[2] Case Med Sch, Cleveland, OH USA
关键词
D O I
10.1086/504487
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Acinetobacter baumannii and Pseudomonas aeruginosa are gram-negative pathogens that target immuno-compromised patients. They express a variety of determinants that confer resistance to a broad array of antimicrobial agents. Mechanisms of resistance include impaired entry through the bacterial outer membrane, production of antibiotic-modifying enzymes, active efflux, and target mutations that reduce antimicrobial affinity. It has been a challenge to identify new agents that have activity against the more resistant variants of these species. Doripenem is a carbapenem in phase 3 trials that has excellent activity against P. aeruginosa and A. baumannii. However, it lacks activity against strains that express resistance to the currently available carbapenems. Tigecycline is a newly licensed glycylcycline that lacks activity against P. aeruginosa but has encouraging activity against many A. baumannii isolates. Resistance to tigecycline can emerge during therapy, however, and is due to expression of multidrug efflux pumps.
引用
收藏
页码:S100 / S105
页数:6
相关论文
共 47 条
[1]   Multidrug-resistant Acinetobacter baumannii [J].
Abbo, A ;
Navon-Venezia, S ;
Orly, HM ;
Krichali, T ;
Siegman-Igra, Y ;
Carmeli, Y .
EMERGING INFECTIOUS DISEASES, 2005, 11 (01) :22-29
[2]  
ACAR JF, 1985, REV INFECT DIS, V7, pS513
[4]   Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition [J].
Azucena, E ;
Mobashery, S .
DRUG RESISTANCE UPDATES, 2001, 4 (02) :106-117
[5]   National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 [J].
Cardo, D ;
Horan, T ;
Andrus, M ;
Dembinski, M ;
Edwards, J ;
Peavy, G ;
Tolson, J ;
Wagner, D .
AMERICAN JOURNAL OF INFECTION CONTROL, 2004, 32 (08) :470-485
[6]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P1087
[7]   Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3 [J].
Chau, SL ;
Chu, YW ;
Houang, ETS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :4054-4055
[8]   Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation [J].
Ciofu, O ;
Riis, B ;
Pressler, T ;
Poulsen, HE ;
Hoiby, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2276-2282
[9]  
DARTOIS N, 2004, 44 INT C ANT AG CHEM
[10]   Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 [J].
Dean, CR ;
Visalli, MA ;
Projan, SJ ;
Sum, PE ;
Bradford, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :972-978